Contact Us

Tekturna
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker Waichman LLP Headlines by Topic

Tekturna

Blood Pressure Medication Tekturna Linked to Potentially Deadly Complications, Says Public Safety Group

Nov 1, 2012
Parker Waichman LLP is reporting that Tekturna, a drug used to treat hypertension, is associated with potentially fatal side effects. According...

Novartis Updating Tekturna Label with Warnings for Diabetes, Kidney Patients. Announces Valturna Market Withdrawal.

Apr 20, 2012
| Parker Waichman LLP
Novartis has announced that it will be making changes to the labels for Tekturna and other aliskiren-based medications regarding serious risks posed...

U.K. Regulator Issues Aliskiren (Rasilez and Tekturna) Update

Mar 9, 2012
| Parker Waichman LLP
U.K.'s health regulator has issued a Drug Safety Update detailing new contraindications for diabetics and kidney patients using the blood pressure...

Novartis Agrees to New Rasilez Warnings

Feb 20, 2012
| Parker Waichman LLP
Following the halt of the ALTITUDE trial, Novartis has agreed to comply with a request by European regulators change the label for its blood pressure...

Page 1/1

Law Dragon Best Lawyers Peer Review Rated Avvo Protected by Copyscape Web Copyright Protection Software php-5